Pear also recently announced a deal with California's Medicaid program that involves supporting a pilot project to help people with stimulant use disorder.
Pear Therapeutics announced today that its reSET and reSET-O prescription digital therapeutics have been added to Florida’s Medicaid preferred drug list.
“Pear applauds Florida leadership for bringing reSET and reSET-O to its millions of Medicaid members in its persistent efforts to tackle the addiction crisis and bring innovative treatment options to those seeking recovery,” Julia Strandberg, MBA, Chief Commercial Officer of Pear Therapeutics.
The announcement about inclusion on Florida’s Medicaid preferred drug lists comes on the heels of a company announcement about a California Medicaid pilot program for treatment of stimulant use disorder that involves use of Pear’s services.
ReSET is used as a monotherapy for patients 18 years of age or older with substance use disorder related to alcohol, cannabis, cocaine, and methamphetamine. ReSET-O is used in combination with buprenorphine-based medication- assisted treatment for patients 18 years of age or older with opioid use disorder.
According to Pear, the Florida Medicaid program has an enrollment of approximately five million, the third highest in the country.